The 2005 Dolph Adams awards and the state of the Journal of Leukocyte Biology
J. Oppenheim
DOI: https://doi.org/10.1189/jlb.0805480
2006-01-01
Journal of Leukocyte Biology
Abstract:It has been eight years since the Society of Leukocyte Biology councilors initiated cash awards in honor of Dolph Adams. The $1000 award was established to recognize the most highly cited research paper and review article published in the Journal of Leukocyte Biology (JLB). The award is based on the number of citations over the past 5 years as a measure of the impact of the papers. The prizes are awarded to the corresponding authors who decide how to share it with their coauthors. The 2004 Dolph Adams Award winner who had the highest number of citations from 1999 through 2003 in the review category with 173 citations was coauthored by Cees van Kooten and Jacques Banchereau and was entitled, “CD40-CD40 ligand” (J. Leukoc. Biol. 67, 2–17, 2000). The most highly cited award-winning research article with 91 citations was by Hong-Bing Shu, Wen-Hui Hu, and Holly Johnson, entitled “TALL-1 is a novel member of the TNF family that is down-regulated by mitogens” (J. Leukoc. Biol. 65, 680 – 683, 1999). It is one of the highlights of my role as Editor-in-Chief of JLB to notify authors that they have won the Dolph Adams Award. For 2005, the most highly cited research article with 100 citations was by Bryan W. Jones, Terry K. Means, Kurt A. Heldwein, Marc A. Keen, Preston J. Hill, John T. Belisle, and Matthew J. Fenton, entitled “Different Toll-like receptor agonists induce distinct macrophage responses” (J. Leukoc. Biol. 69, 1036–1044, 2001). The authors are usually very pleased to hear such good news. For Matthew Fenton, the news provided additional recognition of his successful research career, in particular, as he recently left his laboratory and position as professor of Medicine, Immunology and Microbiology at the University of Maryland Medical School to become chief of the Asthma, Allergy and Inflammation Branch in the Extramural Division of National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH). However, as he is now in an executive managerial position with the federal government, rigorous ethical requirements were applicable, and he needed permission from a NIH conflict-of-interest committee to accept this award. I had to document that the award was longstanding and bonafide, that it was sponsored by a society of scientists independent of biotechnology and pharmaceutical interests, that the funds for the award came collectively from the scientific members of the society, and that it was democratically awarded based on objective criteria. Could there have been a concern that undue influence exerted by this award might alter the course of federal research policy and administration? Fortunately, the committee approved Dr. Fenton’s award, and he is now free to split it amongst all seven coauthors. It is to Dr. Fenton and his colleagues’ credit that their paper was actually based on a rational hypothesis. They proposed in 1999 that as the sequence of the intracellular signaling domains for Toll-like receptor 2 (TLR2) and TLR4 was somewhat different, this could actually result in the activation of different signal transduction pathways and gene targets; and TLR4mediated activation of nuclear factor (NF)B still occurred in knockout mice lacking the adaptor protein MyD88, whereas TLR2 engagement failed to activate NFB, thus indicating that the signal transduction pathways used by these to TLR proteins were not identical. They subsequently compared the responses of cultured macrophages stimulated by Mycobacterium tuberculosis (Mtb) culture filtrates. They observed that the resultant culture filtrates activated cells via TLR2 and tentatively identified the responsible components of Mtb as the glycolipids lipoarabinomannan and phosphatidylinositol dimannoside. This represented the first identification of glycolipid ligands for TLR2. These glycolipid TLR2 ligands and the TLR4 ligand Escherichia coli lipopolysaccharide induced the secretion of tumor necrosis factor by macrophages. In contrast, only TLR4 engagement resulted in the production of nitric oxide. This highly cited, pioneering study stimulated considerable research, resulting in the mapping of differences in signaling by the various TLRs over the following 4 years. The other coauthors have since pursued various careers. Bryan Jones has evolved from being a lab technician to being a law student with an interest in biotechnology. Terry Means, who was a graduate student in 2001, is now an instructor at Harvard’s Massachusetts General Hospital. Kurt Heldwein, who was a postdoctoral fellow in 2001, is now a staff scientist at the Novartis Institutes for Biomedical Research. Preston Hill is a research associate in the Department of Microbiology, Immunology, and Pathology at Colorado State University, where Dr. John Belisle holds the position of associate professor. Marc Keen is currently a research technologist at the University of Nebraska Medical Center. It is evident from the above that life goes on but that authors of award-winning papers use their research experience in their subsequent careers.